Latest Period
Q2 2026
Security Snapshot
Aura Biosciences, Inc. - Common Stock (AURA) Institutional Ownership
CUSIP: 05153U107
13F Institutional Holders and Ownership History from Q4 2021 to Q2 2026
Institutions Reporting
145
Shares (Excl. Options)
95,392,743
Price
$7.10
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- AURA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 95,392,743
- Total 13F value
- $677,298,021
- Portfolio coverage rank
- 0%
- Share change
- +42,002,399
- Value change
- +$301,163,730
- Number of holders
- 145
- Shares outstanding
- 104,481,265
- SEC-reported price per share
- $7.05
- Insider filing price
- $7.05
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AURA - Aura Biosciences, Inc. - Common Stock is tracked under CUSIP 05153U107.
- 145 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 125 to 145 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $340,347,350 to $677,298,021.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 145 institutions filings for Q2 2026.
Security key
05153U107
Latest holder period
Q2 2026
13F holders
145
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
AURA full holder history
Aura Biosciences, Inc. SEC filings
Aura Biosciences, Inc. company facts
Aura Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 05153U107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
AURA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 9.9% | $64,540,664 | 9,533,333 | Chen Yu | 05 May 2026 | |||
| Adage Capital Management, L.P. | 8.4% | $64,640,487 | 9,104,294 | Adage Capital Management, L.P. | 30 Jun 2026 | |||
| Frazier Life Sciences Public Fund, L.P. | 5.6% | -12% | $41,231,546 | +$12,603,920 | 5,807,260 | +44% | Frazier Life Sciences Public Fund, L.P. | 30 Jun 2026 |
| Long Focus Capital Management, LLC | 4.9% | -24% | $36,349,032 | +$12,780,000 | 5,119,582 | +54% | LONG FOCUS CAPITAL MANAGEMENT, LLC | 30 Jun 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.6% | +25% | $30,091,360 | +$10,524,518 | 4,701,775 | +54% | Suvretta Capital Management, LLC | 30 Jun 2025 |
| BlackRock, Inc. | 4.4% | -20% | $32,536,212 | +$8,849,753 | 4,582,436 | +37% | BlackRock, Inc. | 30 Jun 2026 |
| Advent Life Sciences LLP | 3.3% | $11,768,148 | 2,071,857 | Rajesh Parekh, Ph.D. | 13 Feb 2026 |
As of 30 Jun 2026, 145 institutional investors reported holding 95,392,743 shares of Aura Biosciences, Inc. - Common Stock (AURA). This represents 91% of the company’s total 104,481,265 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
79%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.1% | 9,533,333 | 1.6% | $67,686,664 | |
| MONTANOVA CAPITAL, LLC | 6.9% | 7,206,217 | +65% | 1.1% | $51,164,141 |
| Frazier Life Sciences Management, L.P. | 6.8% | 7,100,000 | +39% | 1.1% | $50,410,000 |
| Long Focus Capital Management, LLC | 4.9% | 5,119,582 | +11% | 1.5% | $36,349,032 |
| BlackRock, Inc. | 4.5% | 4,707,674 | +31% | 0% | $33,424,486 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.4% | 4,640,000 | -4.9% | 0.05% | $32,944,000 |
| Caligan Partners LP | 4.1% | 4,298,248 | +1770% | 1.5% | $30,517,561 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 4,100,342 | +83% | 0% | $29,112,428 |
| FCPM III SERVICES B.V. | 3.9% | 4,053,775 | 3.8% | $28,781,803 | |
| ORBIMED ADVISORS LLC | 3.2% | 3,333,333 | 0.45% | $23,666,664 | |
| Medicxi Ventures Management (Jersey) Ltd | 2.9% | 3,039,892 | 0% | 12% | $21,583,233 |
| Nantahala Capital Management, LLC | 2.8% | 2,951,030 | +39% | 1.3% | $20,952,313 |
| Jupiter Topco LLC | 2.4% | 2,500,000 | 0% | 0.01% | $17,787,500 |
| RA CAPITAL MANAGEMENT, L.P. | 2.4% | 2,500,000 | 0.15% | $17,750,000 | |
| Balyasny Asset Management L.P. | 2.3% | 2,354,619 | +322% | 0.03% | $16,717,795 |
| FRANKLIN RESOURCES INC | 2% | 2,072,726 | 0% | 0% | $14,716,355 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 1,754,721 | +34% | 0% | $12,462,919 |
| Redmile Group, LLC | 1.6% | 1,666,667 | 0.79% | $11,833,336 | |
| EcoR1 Capital, LLC | 1.6% | 1,666,667 | 0.59% | $11,833,336 | |
| Trails Edge Capital Partners, LP | 1.4% | 1,443,333 | 1.6% | $10,247,665 | |
| Foresite Capital Management VI LLC | 1.3% | 1,333,334 | 1.5% | $9,466,671 | |
| STATE STREET CORP | 1.2% | 1,222,984 | +27% | 0% | $8,683,186 |
| Woodline Partners LP | 1.2% | 1,210,183 | 0.03% | $8,592,299 | |
| Vivo Capital, LLC | 1.1% | 1,166,667 | 0.76% | $8,283,336 | |
| Bellevue Group AG | 1.1% | 1,166,667 | 0.17% | $8,283,336 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q2 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 95,392,743 | $677,298,021 | +$301,163,730 | $7.10 | 145 |
| 2026 Q1 | 50,880,612 | $340,347,350 | +$4,373,812 | $6.69 | 125 |
| 2025 Q4 | 50,234,935 | $273,791,080 | -$8,935,762 | $5.45 | 116 |
| 2025 Q3 | 51,649,516 | $319,192,259 | +$6,254,107 | $6.18 | 106 |
| 2025 Q2 | 50,616,053 | $316,863,119 | +$67,408,487 | $6.26 | 102 |
| 2025 Q1 | 39,264,901 | $230,096,030 | -$11,860,142 | $5.86 | 91 |
| 2024 Q4 | 39,449,434 | $324,276,778 | +$16,157,250 | $8.22 | 93 |
| 2024 Q3 | 36,866,668 | $329,191,609 | -$25,783,402 | $8.91 | 81 |
| 2024 Q2 | 39,765,227 | $300,437,451 | +$3,314,060 | $7.56 | 75 |
| 2024 Q1 | 39,115,323 | $307,072,789 | +$16,222,241 | $7.85 | 77 |
| 2023 Q4 | 36,998,812 | $327,811,496 | +$89,731,106 | $8.86 | 71 |
| 2023 Q3 | 26,323,010 | $236,119,190 | -$5,574,466 | $8.97 | 62 |
| 2023 Q2 | 27,066,492 | $334,426,517 | +$24,980,886 | $12.35 | 59 |
| 2023 Q1 | 25,069,599 | $232,645,346 | +$10,922,124 | $9.28 | 57 |
| 2022 Q4 | 23,806,818 | $250,037,016 | +$78,469,205 | $10.50 | 49 |
| 2022 Q3 | 16,317,002 | $295,663,462 | +$9,714,465 | $18.12 | 43 |
| 2022 Q2 | 15,793,428 | $223,796,376 | +$29,644,466 | $14.17 | 42 |
| 2022 Q1 | 13,702,730 | $298,756,000 | +$9,092,301 | $22.00 | 34 |
| 2021 Q4 | 13,081,587 | $220,131,000 | +$220,131,000 | $16.98 | 32 |